The firm is focused on the creation of: "transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome type 2 and dystrophic epidermolysis bullosa."

The company states: "Based on aunique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind."